Hejab Imteyaz, MPH, MD
Assistant Professor

Biography
Hejab Imteyaz, MD, MPH, assistant professor of PM&R, completed her physical medicine & rehabilitation residency at Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY in 2015.Dr. Imteyaz received a Masters of Public Health from George Washington University, Washington, DC, in 2002.

After completing medical school at Dow Medical College and residency at Civil Hospital in Pakistan, Dr. Imteyaz pursued a career in research at the Johns Hopkins University, School of Medicine in Baltimore, MD. She has participated in International health projects aiming to develop and distribute online training materials in physical medicine rehabilitation for the local health care providers.

Specialized Areas of Interest
General rehabilitation

CONTACT
412-232-8918
imteyzh@upmc.edu

Board Certifications
Physical Medicine & Rehabilitation

Education & Training
Medicine and Surgery, Dow Medical College, 1996
MPH, George Washington University, 2002
Surgical Residency, Montefiore Medical Center/Albert Einstein College of Medicine, 2012
PM&R Residency, Montefiore Medical Center/Albert Einstein College of Medicine, 2015

Selected Publications
Additional publications can be found at Dr. Imteyaz's PubMed collection.

Ascites in Children: a Single Center Experience of 27 years.”Karnsakul W1, Ingviya T, Seaberg E, Laengvejkal P, Imteyaz H, Vasilescu A, Schwarz KB, Scheimann AO.” J Pediatr Gastroenterol Nutr. 2016 Mar 31.

Unusual case of hypothyroidismin an infant with hepatic hemangiomaImteyaz Hejab, Karnsakul W, Levine MA, Burrows PE, Benson J, Hsu S, Schwarz KB. . Journal Pediatrics Gastroenterol Nutr. 2012 May;54(5):692-5.

‘HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia’.Dura nd CM, O’connell KA, Apuzzo LG, Langan SJ, Imteyaz H, Ahonkhai AA, Williams TM, Margolick JB, Blankson JN. AIDS. 2010 Jul 27.

Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2. AIDSMargolick JB, Imteyaz H, Gallant JE, Langan SJ, Dinoso JB, Siliciano J, Blankson J, Nilles TL, Smith KA, Apuzzo LG. . 2010 Mar 27;24(6):932-5.

HIV-1 Evolution Following Transmission to an HLA-B*5801 Positive Subject. Karen A. O’Connell, Jie Xu, Anna P. Durbin, Linda G. Apuzzo, Hejab Imteyaz, Thomas M. Williams, Stuart C. Ray, Joseph B. Margolick, Robert F. Siliciano, and Joel N. Blankson. Journal of Infectious Diseases, 2009 Dec 15;200(12):1820-4.

Immunological and Virological Effects of Daily Low Dose Interleukin-2 (LD IL-2) in a Patient Who Maintained an Undetectable HIV Viral Load (VL) for 14 Months Following Cessation of HAART and IL-2. Poster presentedat: HIV Immunobiology: From Infection to Immune Control (X4)J Margolick, H Imteyaz, J Gallant, P Barditch-Crovo, D Dabitao, J Bream, S Langan, J Blankson, J Siliciano, R Siliciano, JDinoso,L Apuzzo,. (2009, March). ; Keystone, CO. 2009.

Objective assessment of gaitin normal-pressure hydrocephalus. Williams MA, Thomas G, de Lateur B, Imteyaz H, Rose JG, Shore WS, Kharkar S, Rigamonti D. Am J Phys Med Rehabil. 2008 Jan;87(1):39-45.

Contributed to the report; Financing Vaccines in the 21st Century: Assuring Access and Availability (2003), Institute of Medicine, of Sciences, Washington DC.